וקטור פלוס 16012.5
unipharm ltd, israel - hydrochlorothiazide; valsartan - טבליה - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan - valsartan - for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.
וקטור 160
unipharm ltd, israel - valsartan - טבליה - valsartan 160 mg - valsartan
וקטור 80
unipharm ltd, israel - valsartan - טבליה - valsartan 80 mg - valsartan
וקטור 80
unipharm ltd, israel - valsartan - טבליה - valsartan 80 mg - valsartan
ואלסרטן- מדו 160 מג
a.l. medi-market ltd. - valsartan - טבליות מצופות פילם - valsartan 160 mg - valsartan
ואלסרטן- מדו 80 מג
a.l. medi-market ltd. - valsartan - טבליות מצופות פילם - valsartan 80 mg - valsartan
וקטור פלוס 16012.5
unipharm ltd, israel - hydrochlorothiazide; valsartan - טבליה - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan
וקטור פלוס 16025
unipharm ltd, israel - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan
וקטור 40
unipharm ltd - valsartan 40 mg - film coated tablets - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalizations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.
וקטור פלוס 8012.5
unipharm ltd, israel - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan